Metastatic Clinical Trials in Nashville, Tennessee
145 recruitingNashville, Tennessee
Showing 1–20 of 145 trials
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 1Phase 2
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.428 enrolled7 locationsNCT07287995
Recruiting
Phase 1Phase 2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 1
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)57 enrolled6 locationsNCT05422794
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche792 enrolled45 locationsNCT03424005
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Breast CancerEndometrial CancerAdvanced Solid Tumor+2 more
Alterome Therapeutics, Inc.110 enrolled51 locationsNCT06533059
Recruiting
Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC61 enrolled1 locationNCT05187832
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled4 locationsNCT07288359
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Lung CancerAdvanced Solid TumorMetastatic Solid Tumor+2 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 2
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Metastatic Triple-Negative Breast CarcinomaMetastatic HER2-Negative Breast Carcinoma
Vanderbilt-Ingram Cancer Center160 enrolled1 locationNCT05770531